I can see no relationship at all between CuATSM and MCC950. CuATSM is targetting the electron transport chain within mitochondria. MCC950 is targetting the inflammatory activity of microglia.

In the article about CuATSM, the section at the end, titled "Australia continues to forge ahead" (and the photograph of MJF), refer to the work on MCC950 being done at the University of Queensland. I can see how this section could cause confusion.